These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25382700)

  • 1. Efficacy of telavancin, a lipoglycopeptide antibiotic, in experimental models of Gram-positive infection.
    Hegde SS; Janc JW
    Expert Rev Anti Infect Ther; 2014 Dec; 12(12):1463-75. PubMed ID: 25382700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
    Laohavaleeson S; Kuti JL; Nicolau DP
    Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.
    Karlowsky JA; Nichol K; Zhanel GG
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S58-68. PubMed ID: 26316559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telavancin: a new lipoglycopeptide for gram-positive infections.
    Smith WJ; Drew RH
    Drugs Today (Barc); 2009 Mar; 45(3):159-73. PubMed ID: 19436839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.
    Adamantia L; Antoni T
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):803-12. PubMed ID: 27158752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical positioning of telavancin in Europe.
    Masterton R; Cornaglia G; Courvalin P; Lode HM; Rello J; Torres A
    Int J Antimicrob Agents; 2015 Mar; 45(3):213-20. PubMed ID: 25600892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.
    Rubinstein E; Corey GR; Stryjewski ME; Kanafani ZA
    Expert Opin Pharmacother; 2011 Dec; 12(17):2737-50. PubMed ID: 22077833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults.
    Chang MH; Kish TD; Fung HB
    Clin Ther; 2010 Dec; 32(13):2160-85. PubMed ID: 21316534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
    Pfaller MA; Rhomberg PR; Sader HS; Mendes RE; Jones RN
    J Chemother; 2010 Oct; 22(5):304-11. PubMed ID: 21123152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
    Stryjewski ME; Chu VH; O'Riordan WD; Warren BL; Dunbar LM; Young DM; Vallée M; Fowler VG; Morganroth J; Barriere SL; Kitt MM; Corey GR;
    Antimicrob Agents Chemother; 2006 Mar; 50(3):862-7. PubMed ID: 16495243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
    Stryjewski ME; Graham DR; Wilson SE; O'Riordan W; Young D; Lentnek A; Ross DP; Fowler VG; Hopkins A; Friedland HD; Barriere SL; Kitt MM; Corey GR;
    Clin Infect Dis; 2008 Jun; 46(11):1683-93. PubMed ID: 18444791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
    Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
    Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telavancin: a novel lipoglycopeptide antimicrobial agent.
    Attwood RJ; LaPlante KL
    Am J Health Syst Pharm; 2007 Nov; 64(22):2335-48. PubMed ID: 17989443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telavancin: a novel lipoglycopeptide.
    Saravolatz LD; Stein GE; Johnson LB
    Clin Infect Dis; 2009 Dec; 49(12):1908-14. PubMed ID: 19911938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.
    Krause KM; Barriere SL; Kitt MM; Benton BM
    Diagn Microbiol Infect Dis; 2010 Oct; 68(2):181-5. PubMed ID: 20846593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.
    Leonard SN; Rybak MJ
    Pharmacotherapy; 2008 Apr; 28(4):458-68. PubMed ID: 18363530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
    Sandrock CE; Shorr AF
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.
    Wenzler E; Rodvold KA
    Clin Infect Dis; 2015 Sep; 61 Suppl 2():S38-47. PubMed ID: 26316557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.